|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
The Auto Beat
Byte of the Apple
Europe Insight
Eye on Asia
Getting In
Investing Insights
The New Entrepreneur
NEXT: Innovation Tools & Trends
On Media
Technology at Work
The Tech Beat
Traveler's Check
TECHNOLOGY
Product Reviews
Tech Stats
Hands On
AUTOS
Home Page
Auto Reviews
Car Care & Safety
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip FINANCE Investing: Europe Annual Reports Bloomberg BW50 SCOREBOARDS Hot Growth Companies: 2008 Mutual Funds Info Tech 100 B-SCHOOLS Undergrad Programs Rankings & Profiles |  |
JULY 25, 2005
Spectrum's Cancer Drugs Could Be Winners  Biotechs got battered earlier this year, but the big-caps are winning back investor interest. John McCamant, editor of the Medical Technology Stock Letter, says small-cap biotechs, which bore the brunt of the selling, are now where the values are. Dan D'Pietro of hedge fund ProMedCapital is high on Spectrum Pharmaceuticals (SPPI
) (SPPI), whose stock is down from 6.90 in mid-March to 4.40 now. The company has yet to make a dime, but it has a number of anticancer agents in advanced clinical trials, including Satraplatin, an oral drug for prostate cancer. The Food & Drug Administration has given Satraplatin a "fast-track" designation for quick action upon completion of tests now in progress in Europe. Satraplatin, says D'Pietro, is also being tested for ovarian and small-cell lung cancer. Spectrum's partner, Germany's GPC Biotech (GPCB
), is funding the trials. Spectrum will ink a pact with a major drug company to market Satraplatin, says one investor close to the company. Ren Benjamin of investment firm Rodman & Renshaw rates it "outperform/speculative risk," with a price target of 12. Spectrum, he says, should report interim clinical results on Satraplatin by early 2006.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial Get BusinessWeek directly on your desktop with our RSS feeds.  Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2005, Bloomberg L.P.Terms of Use | Privacy Notice |
Printer-Friendly Version